Integrating AI Across the Pharmaceutical Value Chain

The AI opportunity in pharma is growing, as the technology moves beyond the hype to yield tangible results. Since 2023's milestone achievement of the first AI-discovered drug candidates entering human trials, the tools continue to demonstrate their transformative potential across R&D. More remarkably, these tools are fundamentally reshaping drug economics, challenging long-held assumptions about development costs and timelines.  PwC estimates that pharmaceutical companies that successfully industrialise AI use cases across their organisations, could double their operating profits by 2030.

While drug discovery breakthroughs capture headlines, AI's promise extends further, promising a paradigm shift in how clinical trials are conducted and companies engage with patients. The aim is now to both realise and execute on opportunities across the entire pharma value chain. 

Yet transitioning from pilot projects to scaled implementation presents unique challenges, including the navigation of regulatory requirements, data management challenges, and organisational readiness. Crucially, as pharmaceutical companies scale their AI initiatives, they must manage to balance innovation with the need to instill trust among stakeholders.

This Financial Times webinar, in partnership with PwC, will feature an in-depth exploration of AI’s potential within the pharmaceutical industry. Gain insights into cutting-edge applications, untapped opportunities for innovation, and strategies to address the barriers to implementation to create lasting, measurable AI impact.

ROI & Scale

How are pharmaceutical companies leveraging AI to accelerate drug discovery, drug development and clinical trials? What key applications are delivering measurable ROI, and how can these be operationalised across the enterprise?

Value of AI

Where is AI creating the most value across the pharmaceutical value chain - beyond drug discovery, where are the opportunities for profitable growth? 

Build, Buy, or Partner? 

How should pharmaceutical companies approach AI integration - through in-house development, acquisitions, or strategic partnerships?

FT Live webinars are fully digital event experiences delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice